UK markets closed

Centessa Pharmaceuticals Limited (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.60+0.22 (+1.93%)
At close: 1:00PM EST

Centessa Pharmaceuticals Limited

The Dorothy Hodgkin Building Babraham
Research Campus Babraham
Cambridge CB22 3FH
United Kingdom
44 73 9178 9784
http://www.centessa.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees70

Key executives

NameTitlePayExercisedYear born
Dr. James Edward Coleman Ph.D.Co-Founder & COO of LockBody Therapeutics163.88kN/AN/A
Dr. Trevor Baglin Ph.D.Co-Founder, Chief Medical Officer - ApcinteX & Chief Medical Officer - Z Factor65.55kN/AN/A
Prof. James HuntingtonFounder & CEO of Z Factor204.85kN/AN/A
Dr. Nicholas Morrell M.D., MBBSCo-Founder & CEO of Morphogen-IX320.94kN/AN/A
Dr. William James Jonathan Finlay B.Sc., Ph.D.Co-Founder & CEO of LockBody Therapeutics163.88kN/AN/A
Dr. Saurabh Saha M.D., Ph.D.CEO & DirectorN/AN/A1977
Dr. Gregory M. Weinhoff M.B.A., M.D., MBAChief Financial OfficerN/AN/A1971
Ms. Marella ThorellChief Accounting OfficerN/AN/A1967
Dr. Thomas S. Templeman Ph.D.Chief Technology OfficerN/AN/A1959
Dr. David M. ChaoChief Admin. OfficerN/AN/A1968
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.

Corporate governance

Centessa Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.